NEW YORK, NY / ACCESSWIRE / March 15, 2016 / Islet Sciences, Inc. (OTC: ISLT) ("Islet Sciences"), a biopharmaceutical company focused on developing new technologies and medicines for the early detection, intervention, and pre-treatment to prevent and slow the progression of metabolic disease, today announced that it has appointed Thomas J. Kindt, Ph.D., to the Company's Scientific Advisory Board, effective March 14, 2016.

Dr. Kindt, has previously served as Chief Scientific Officer of Diomics Corp., of San Diego and InNexus Biotechnology. For the past 11 years Dr. Kindt has served as an adjunct member of the Department of Biology at the University of New Mexico and authored a major textbook on immunology. From 1995 to 2005, Dr. Kindt served as Director, Division of Intramural Research, NIAID, NIH, in Bethesda, Maryland. There he was responsible for the management of the Division including 1,300 staff members, as well as overseeing an annual budget of $340 Million, and research facilities in Bethesda, Rockville and Frederick, Maryland; Hamilton, Montana; Bamako, Mali, and Rakai District, Uganda.

Dr. Kindt holds a Bachelor of Science in Chemistry (cum laude) from Thomas More College and Ph.D., in BioChemistry from the University of Illinois at Urbana-Champaign.

"Dr. Kindt is an industry veteran with an extensive background in Life Sciences, having served on numerous prestigious boards and leading scientific committees," stated, John Steel, Director of Islet Sciences, Inc. "In addition to being a distinguished published scholar, he holds several significant industry patents and we welcome him to our esteemed Scientific Advisory Board."

Dr. Kindt stated, "I am pleased to join the Scientific Advisory Board of Islet Sciences. The problems posed by metabolic disease and their early detection and treatment continue to be a challenge. Together, we will be working to help advance the unmet medical needs of so many."

About Islet Sciences

Islet Sciences, Inc., a biopharmaceutical company based in New York, NY, is developing new medicines and technologies for the treatment of metabolic disease. For more information, please visit http://www.isletsciences.com.

Forward-Looking Statements

 Certain statements in this press release constitute forward-looking statements. These statements are not historical facts but instead represent only Islet Science's belief regarding future events, many of which, by their nature, are inherently uncertain and outside Islet Science's control. It is possible that actual results will differ, possibly materially, from the anticipated results indicated in these statements. Factors that could affect Islet Science's financial and other results are included in Islet Science's periodic filings with the SEC pursuant to the Securities Exchange Act of 1934.

CONTACT:

Islet Sciences
John Steel, Director
Phone: + 1 858-692-7897

SOURCE: Islet Sciences, Inc.